Plain-English translation of NCT03267888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial studied whether , an immunotherapy drug, combined with low-dose radiation therapy could help patients whose multiple myeloma (a blood cancer) had become resistant to or relapsed after other treatments. The trial tested whether using these two approaches together—radiation targeted at specific myeloma sites plus the medication given intravenously—would be safe and effective. Researchers followed participants for up to 2 years to see how well the combined treatment worked and what side effects occurred.
Multiple myeloma patients often exhaust standard treatment options, leaving them with few choices when their disease comes back or stops responding to therapy. This trial explored whether combining the medication with radiation could unlock a new way to help these patients by boosting the immune system's ability to fight the cancer.
Participants received a single low-dose radiation treatment on day 1, followed by an intravenous infusion of the medication on day 2 or 3. This cycle of the medication was then repeated every 3 weeks for up to 2 years, as long as the cancer did not progress and side effects remained manageable. After completing treatment, participants were followed up with a visit at 30 days and then every 12 weeks to monitor their response and any lasting effects from the therapy.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States